Agios Pharmaceuticals Q1 2024 GAAP EPS $(1.45) Beats $(1.64) Estimate, Sales $8.189M Miss $8.370M Estimate
Agios Pharmaceuticals Q1 2024 GAAP EPS $(1.45) Beats $(1.64) Estimate, Sales $8.189M Miss $8.370M Estimate
Agios Pharmaceuticals 2024年第一季度GAAP每股收益美元（1.45美元）超過預期（1.64美元），銷售額爲818.9萬美元，低於83.70萬美元的預期
Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.45) per share which beat the analyst consensus estimate of $(1.64) by 11.59 percent. This is a 1.36 percent increase over losses of $(1.47) per share from the same period last year. The company reported quarterly sales of $8.189 million which missed the analyst consensus estimate of $8.370 million by 2.17 percent. This is a 46.00 percent increase over sales of $5.609 million the same period last year.
Agios Pharmicals（納斯達克股票代碼：AGIO）公佈的季度虧損爲每股1.45美元，比分析師普遍預期的1.64美元（1.64美元）高出11.59％。這比去年同期每股虧損1.47美元（1.47美元）增長了1.36％。該公司公佈的季度銷售額爲818.9萬美元，比分析師普遍預期的8370萬美元低2.17％。這比去年同期的560.9萬美元銷售額增長了46.00％。